Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer.
Noto A, De Vitis C, Roscilli G, Fattore L, Malpicci D, Marra E, Luberto L, D'Andrilli A, Coluccia P, Giovagnoli MR, Normanno N, Ruco L, Aurisicchio L, Mancini R, Ciliberto G.
Noto A, et al. Among authors: aurisicchio l.
Oncotarget. 2013 Aug;4(8):1253-65. doi: 10.18632/oncotarget.1141.
Oncotarget. 2013.
PMID: 23896512
Free PMC article.